Genetic Analysis of Purine Metabolism in Leishmania donovani*

(Received for publication, April 21, 1997, and in revised form, May 21, 1997)

Ho-Yon Hwang and Buddy Ullman Dagger

From the Department of Biochemistry and Molecular Biology, Oregon Health Sciences University, Portland, Oregon 97201-3098

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

To dissect the contributions of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and adenosine kinase (AK) to purine salvage in Leishmania donovani, null mutants genetically deficient in HGPRT and/or APRT were generated by targeted gene replacement in wild type cells and preexisting mutant strains lacking either APRT or AK activity. These knockouts were obtained either by double targeted gene replacement or by single gene replacement followed by negative selection for loss-of-heterozygosity. Genotypes were confirmed by Southern blotting and the resultant phenotypes evaluated by enzymatic assay, resistance to cytotoxic drugs, ability to incorporate radiolabeled purine bases, and growth on various purine sources. All mutant strains could propagate in defined growth medium containing any single purine source and could metabolize exogenous [3H]hypoxanthine to the nucleotide level. The surprising ability of mutant L. donovani lacking HGPRT, APRT, and/or AK to incorporate and grow in hypoxanthine could be attributed to the ability of the parasite xanthine phosphoribosyltransferase enzyme to salvage hypoxanthine. These genetic studies indicate that HGPRT, APRT, and AK, individually or in any combination, are not essential for the survival and growth of the promastigote stage of L. donovani and intimate an important, if not crucial, role for xanthine phosphoribosyltransferase in purine salvage.


INTRODUCTION

Protozoan parasites cause a variety of devastating and often fatal diseases in humans and their domestic animals. The treatment and control of parasitic diseases, however, is severely compromised by the dearth of effective and selective antiparasitic therapies. Many of the current antiparasitic drugs cause severe toxicity in the host, a predicament that can be attributed to lack of target specificity. Moreover, these drugs are potentially mutagenic and/or carcinogenic, they often require protracted courses with multiple drug administrations, and therapeutic unresponsiveness and drug resistance have exacerbated the necessity for new and improved antiparasitic agents.

The institution of a rational therapeutic regimen for the treatment and prevention of parasitic diseases hinges upon exploitation of fundamental biochemical disparities between parasite and host. Perhaps the most striking metabolic discrepancy between parasites and humans is the purine pathway. Whereas mammalian cells can synthesize the purine heterocycle de novo, all protozoan parasites studied thus far are auxotrophic for purines (1). As a consequence, each genus of parasite has evolved a unique complement of purine salvage enzymes that enable the organism to scavenge host purines. Unique features of the purine salvage pathway of Leishmania and Trypanosoma constitute the basis for the susceptibility of these genera to several pyrazolopyrimidine analogs of naturally occurring purine bases and nucleosides (2, 3). The intact parasites efficiently metabolize these analogs to the nucleotide level, whereas mammalian cells are essentially incapable of these metabolic transformations. One of these pyrazolopyrimidines, allopurinol (4-hydroxypyrazolo[3,4]pyrimidine, HPP),1 a drug that is nontoxic to humans and is widely used in the treatment of hyperuricemia and gout (4), has demonstrated significant therapeutic efficacy in patients with either cutaneous leishmaniasis (5) or chronic Chagas disease (6).

Leishmania donovani, the causative agent of visceral leishmaniasis, is a digenetic parasite that exists as an extracellular promastigote within the insect vector, members of the phlebotomine sandfly family, and as a nonmotile intracellular amastigote within the phagolysosome of macrophages and other cells of the reticuloendothelial system of the mammalian host. L. donovani expresses a number of enzymes capable of converting preformed purines directly to nucleotides. These enzymes include hypoxanthine-guanine phosphoribosyltransferase (HGPRT; IMP:pyrophosphate phosphoribosyltransferase; EC 2.4.2.8), adenine phosphoribosyltransferase (APRT; AMP:pyrophosphate phosphoribosyltransferase; EC 2.4.2.7), xanthine phosphoribosyltransferase (XPRT; XMP:pyrophosphate phosphoribosyltransferase; EC 2.4.2.22), and adenosine kinase (AK). Leishmania also contain a plethora of purine interconversion enzymes including nucleosidases, phosphorylases, deaminases, and IMP branchpoint enzymes (1). Overall, the purine pathway is divagating and intricate, and this metabolic complexity and the apparent overall diploid nature of the parasite (7-9) has hindered a thorough characterization of the purine pathway in the parasite by straightforward biochemical and genetic approaches.

The ability of Leishmania to undergo a high rate of homologous gene replacement (7, 10-12) and to take up foreign DNAs after transfection (13, 14) now permits an assessment of specific gene function by targeted gene replacement and facilitates the genetic dissection of complex metabolic pathways such as that for purine acquisition. As both the HGPRT (15) and APRT (16) genes and their flanking regions have been isolated, we have examined the relative contributions of HGPRT, APRT, and AK to purine salvage in L. donovani promastigotes by sequentially eliminating each HGPRT and APRT allele from wild type cells and from preexisting mutants lacking either APRT (8) or AK (17) activity by homologous gene replacement and/or direct selection. These strains were created either by replacing each allele sequentially with independent drug resistance markers or by disrupting the first allele with one drug resistance marker and selecting for loss-of-heterozygosity (LOH) with drug pressure to obtain the homozygous null mutant. The new alleles in the heterozygotes and homozygotes were examined by Southern blotting, and the resultant phenotypes of the mutant strains have been evaluated for enzymatic activities, ability to take up purines, drug resistance profiles, and growth properties.


EXPERIMENTAL PROCEDURES

Chemicals and Reagents

[14C]Hypoxanthine, [14C]guanine, [14C]adenine, and [14C]xanthine, all at 56 mCi/mmol, and [3H]adenosine at 32.5 Ci/mmol were obtained from Moravek Biochemicals (Brea, CA). [alpha -32P]dCTP (3000 Ci/mmol) and [alpha -35S]dATP (1320 Ci/mmol) were bought from NEN Life Science Products. All restriction and DNA modifying enzymes were acquired from either New England Biolabs, Inc. or Life Technologies, Inc., and Thermus flavus DNA polymerase was purchased from Epicentre Technologies (Madison, WI). The pX63-NEO and pX63-HYG drug resistance cassettes were furnished by Dr. Stephen Beverley (Harvard Medical School). The sources of all other chemicals and reagents were of the highest quality commercially available.

Cell Culture

Promastigotes of the Sudanese 1S strain of L. donovani were grown in DME-L culture medium (18). Unless otherwise specified, DME-L contains 100 µM xanthine as a purine source. Clonal lines of L. donovani were isolated as colonies on semi-solid DME-L medium containing appropriate selective agent as indicated (18). Initial recipient strains for the transfection experiments reported here included the wild type DI700 line and its two clonal derivatives, TUBA2 and APPB2A3. The isolation and biochemical characterizations of the AK-deficient (ak-) TUBA2 (17) and the APRT-deficient (aprt-) APPB2A3 (8) strains have been reported previously. TUBA2 and APPA2B3 cells and all of their progeny were continuously maintained in either 1 µM tubercidin, a cytotoxic AK substrate (17), or 100 µM 4-aminopyrazolopyrimidine, a subversive substrate of APRT (8), respectively, to ensure retention of the selected phenotype. For the genetic manipulations of the HGPRT and APRT loci described here, DI700, TUBA2, and APPB2A3 cell lines are designated DI700:H+/+A+/+, TUBA2:H+/+A+/+, and APPB2A3:H+/+, respectively, where H refers to HGPRT, A to APRT, and + is the wild type allele (see Table I). No allelic nomenclature is given for the APRT locus of APPB2A3 cells, as the genetic basis for the APRT deficiency in this strain has not been characterized. Sensitivities of wild type and strains created by targeted gene replacement to HPP, 4-aminopyrazolo[3,4]pyrimidine (APP), 4-thiopurinol, and HPP riboside were performed as described (8, 17).

DNA Manipulations

Protocols utilized by this laboratory for obtaining parasite DNA, for Southern blotting, and for nucleotide sequencing have all been described previously (19, 20). The L. donovani HGPRT (15) and APRT (16) were isolated from cosmids as 3.5-kb EcoRI and 5.4-kb BamHI-XbaI restriction fragments, respectively. Flanking regions of the two genes were identified by restriction mapping and Southern blotting. An additional 5.2-kb SalI-EcoRI (21) DNA located immediately 5' to the 3.5-kb EcoRI DNA was also obtained from the HGPRT-containing cosmid to amplify the 5'-flanking region of HGPRT for construction of gene targeting vectors.

Construction of Knockout Vectors

The flanking regions from the HGPRT and APRT loci and the oligonucleotides used for their amplification by the polymerase chain reaction (PCR) have been reported previously (21). The construction and authentication of the pX63-NEO-Delta hgprt and pX63-HYG-Delta aprt plasmids employed in the allelic replacements of the HGPRT and APRT loci, respectively, have also been described (21). pX63-NEO-Delta hgprt contains a 1.7-kb 5' and a 1.8-kb 3'-flanking region from the L. donovani HGPRT encompassing the neomycin phosphotransferase (NEO) gene, while pX-HYG-Delta aprt includes a 1.4-kb 5' and a 1.5-kb 3' flank of the L. donovani APRT circumscribing the hygromycin phosphotransferase (HYG) marker. To generate a HYG construct for replacing the HGPRT locus, the 1.7-kb 5' and 1.8-kb 3' flanks employed for making pX63-NEO-Delta hgprt were reamplified using the PCR conditions described by Hwang et al. (21) and ligated into the appropriate restriction sites within pX63-HYG. The pX63-HYG-Delta hgprt construct was verified for identity and orientation by limited restriction mapping and nucleotide sequencing.

Transfection

Parasites were transfected using electroporation conditions reported previously (11, 21). All targeting constructs were cleaved from their plasmids by digestion with HindIII and BglII just prior to electroporation, isolated on agarose gels, and purified using the GeneClean Kit (Intermountain Scientific Corp., Bountiful, UT). Designation of the targeting DNAs originated from the plasmid nomenclature without the initial letter, e.g. X63-HYG-Delta hgprt from pX63-HYG-Delta hgprt. All transfected cells were grown for 24 h under nonselective conditions prior to the initiation of drug pressure.

Gene Replacements

To generate lines heterozygous at either the HGPRT (hgprt/HGPRT) or APRT (aprt/APRT) locus, L. donovani promastigotes were transfected with the appropriate targeting construct, and heterozygotes were selected by the addition of either 50 µg/ml Geneticin (G418) or hygromycin B to liquid medium or 16 µg/ml G418 or 50 µg/ml hygromycin B to semi-solid medium. Clonal populations were selected on agar plates as described (18). The genotypes of the heterozygotes were determined by Southern blotting using appropriate protein coding and flanking probes.

To generate homozygous null mutants (Delta hgprt or Delta aprt) from the heterozygotes, two strategies were employed. The first required a second round of transfection with an independent drug resistance cassette, i.e. double targeted gene replacement. Using this approach, both G418 and hygromycin were added to the plates to select for parasites in which the wild type allele in the heterozygous recipient had been specifically disrupted by homologous recombination of the second targeting construct. The second protocol for selecting homozygous null mutants at either the HGPRT or APRT loci was to select for LOH by plating in semi-solid agarose to which a toxic substrate of the encoded gene product had been added. Specific selective conditions were 1-3 mM HPP to obtain Delta hgprt clones and 100 µM APP to obtain Delta aprt clones. Selections for LOH at the HGPRT and APRT loci included G418 and/or hygromycin, as specified, in the medium to retain drug resistance cassettes that had been previously integrated at the appropriate locus/loci by targeted gene replacement.

All L. donovani transformants that had integrated copies of either X63-NEO-Delta hgprt, X63-HYG-Delta hgprt, or X63-HYG-Delta aprt into the relevant loci were maintained continuously under selective pressure in the drugs for which they contained resistance markers. In addition, knockout cell lines created by single targeted gene replacement as described above were also grown perpetually in the agent in which they were selected, i.e. 2 mM HPP or 100 µM APP as appropriate.

Enzyme Assays

Exponentially growing L. donovani were harvested in 50 mM Tris, pH 8.0, containing 5 mM MgCl2, and 1 mM dithiothreitol and lysed either by sonication or by three rounds of freeze-thawing. HGPRT (22), APRT (22), and AK (17) activities were measured in 20,000 × g supernatants as reported.

Radiolabel Incorporation Assays

The rate of [14C]hypoxanthine incorporation into phosphorylated metabolites in the absence or presence of excess nonradiolabeled purines was ascertained at room temperature using a slight modification of the DE-81 filter disk method outlined by Iovannisci et al. (17). 108 parasites were harvested by centrifugation, washed with phosphate-buffered saline, and resuspended in 1.0 ml of modified DME-L growth medium lacking the hemin and xanthine components prior to the addition of radiolabel and purine additives. [14C]Hypoxanthine and nonradiolabeled purines were present at 1.8 µM and 100 µM, respectively, in the uptake assays. The assay was terminated by removing 100-µl aliquots of (107) cells, diluting them in ice cold phosphate-buffered saline, and subjecting them to centrifugation. The pelleted cells were washed twice in 1.0 ml of phosphate-buffered saline, lysed in 1% Triton X-100, and blotted onto a 1.5-cm2 piece of DE-81 impregnated paper. The disks were washed as described (17).


RESULTS

Derivation of Mutant Strains by Gene Replacement

A flow chart describing the derivation and lineages of all of the mutant strains that were created as a result of targeted gene replacement and/or direct selection in cytotoxic substrate is depicted in Fig. 1. Three parental recipient clonal cell lines were employed for the transfection experiments, DI700 wild type cells, TUBA2 ak- cells, and APPB2A3 aprt- cells. The three parental cell lines are designated DI700:H+/+A+/+, TUBA2:H+/+A+/+, and APPB2A3:H+/n, respectively (Fig. 1), as their HGPRT and APRT loci have not been targeted by gene replacement vectors. Heterozygotes (hgprt/HGPRT) in which a single wild type HGPRT allele was disrupted by targeted gene replacement approaches were obtained from DI700 (DI700:H+/nA+/+) and TUBA2 (TUBA2:H+/nA+/+) cells with X63-NEO-Delta hgprt as the targeting vector and from APPA2A3 (APPB2A3:H+/h) cells with X63-HYG-Delta hgprt. Homozygous null mutants (Delta hgprt) were then obtained from the three hgprt/HGPRT lines by two independent strategies, either by targeting with the appropriate construct containing the second drug resistance marker (DI700:Hn/hA+/+, TUBA2:Hn/hA+/+, and APPB2A3:Hh/n) or by direct negative selection (DI700:Hn/nA+/+ and TUBA2:Hn/nA+/+) for LOH (see Fig. 1). Nomenclature for all the Delta hgprt cell lines shown in Fig. 1 conforms to that employed for the heterozygotes.


Fig. 1. Pedigree of L. donovani lines obtained by targeted gene replacement and LOH. The lineage of the L. donovani strains derived for these investigations is depicted. Capital letter designations specify the locus, either HGPRT (H) or APRT (A), while superscripts specify the allele, either wild type (+) or those replaced by X63-NEO-Delta hgprt (n), X63-HYG-Delta hgprt (h), or X63-HYG-Delta aprt (h). The three initial strains employed for these genetic analyses include the previously described wild type DI700, ak- TUBA2, and aprt- APPB2A3 strains (8, 17), which are now designated for the purposes of these genetic studies DI700:H+/+A+/+, TUBA2:H+/+A+/+, and APPB2A3:H+/+A+/+, respectively.
[View Larger Version of this Image (22K GIF file)]

The ability to generate Delta hgprt null mutants after only a single round of transfection permitted the creation of L. donovani cell lines in which both wild type alleles of the HGPRT and APRT loci had been displaced, each with a single targeting construct. Cell lines heterozygous at the APRT locus (aprt/APRT) were thus created from the DI700:Hn/nA+/+ and TUBA2:Hn/nA+/+ cell lines, as well as from the parental TUBA2:H+/+A+/+ strain by targeted gene replacement using the X63-HYG-Delta aprt construct. These derivatives were designated DI700:Hn/nA+/h, TUBA2:Hn/nA+/h, and TUBA2: H+/+A+/h, respectively (Fig. 1). Delta aprt clonal progeny, DI700:Hn/nAh/h, TUBA2:Hn/nAh/h, and TUBA2:H+/+Ah/h, were then selected for LOH from the three aprt/APRT heterozygotes in 100 µM APP (Fig. 1).

Southern Blot Analysis

Southern blot analysis verified the existence of the new alleles that had been created after either double or single targeted gene replacement. The maps of the genomic loci for HGPRT and APRT and the novel alleles created by homologous recombination of X63-NEO-Delta hgprt into the HGPRT locus and X63-HYG-Delta aprt into the APRT locus have been reported previously (21). The X63-HYG-Delta hgprt construct and its rearranged allele after insertion into the chromosome are displayed in Fig. 2. The maps of the HGPRT and APRT loci are also included in Fig. 2 to show the location of the probes employed in the Southern blotting experiments. The expected size differences of the wild type and disrupted HGPRT alleles in strains that were generated or employed for these studies can be visualized in Fig. 3. The interrupted HGPRT alleles could be distinguished from the wild type allele by an altered EcoRI restriction pattern (Fig. 3). After cleavage of genomic DNA with EcoRI and hybridization to probe B derived from the 3'-flanking region of HGPRT (see Fig. 2), only the anticipated 4.6-kb EcoRI fragment from the wild type allele was discerned in the three parental, i.e, DI700:H+/+A+/+, APPB2A3:H+/+, and TUBA2:H+/+A+/+, strains in which the HGPRT locus was intact (see Fig. 3, probe B). Although the HGPRT was originally isolated as a 3.5-kb EcoRI fragment (see "Experimental Procedures"), the 4.6-kb EcoRI band is the expected size of the wild type HGPRT allele, as the 3' EcoRI restriction site of the cloned 3.5-kb fragment originates from the cosmid. In contrast, bands of 6.4 and 6.2 kb were observed in those strains in which an HGPRT allele had been targeted by either X63-NEO-Delta hgprt or X63-HYG-Delta hgprt, respectively (Fig. 3). Cell lines heterozygous for HGPRT (H+/h or H+/h) retained the 4.6-kb EcoRI fragment derived from the wild type locus, while HGPRT null mutants (Hn/h or Hn/n) lacked the wild type 4.6-kb EcoRI restriction fragment and exhibited only the expected 6.4- and 6.2-kb displacements by X63-NEO-Delta hgprt and X63-HYG-Delta hgprt, respectively (Fig. 3, probe B). The interruption of the wild type HGPRT allele was verified by hybridization of genomic DNA to probe A corresponding to the coding region of HGPRT (see Fig. 2). The 4.6-kb EcoRI fragment was detected only in cell lines that were wild type or heterozygous at the HGPRT locus, i.e. the H+/+, H+/n, and H+/h strains and not in Delta hgprt null mutants that were derived by either double targeted (Hn/h) or single targeted (Hn/n) gene replacement (Fig. 3, probe A).


Fig. 2. Restriction maps of the HGPRT and APRT genomic loci, the X63-HYG-Delta hgprt targeting construct, and the novel allele hgprt allele created by homologous recombination of the wild type HGPRT allele with X63-HYG-Delta hgprt. Restriction maps of the wild type HGPRT locus (A), the X63-HYG-Delta hgprt targeting construct (B), the rearranged hgprt locus after homologous recombination with X63-HYG-Delta hgprt (C), and the wild type APRT locus (D) are shown. Restriction maps of X63-NEO-Delta hgprt and X63-HYG-Delta aprt and their rearranged loci after homologous recombination have been published previously (21). The sizes of the fragments expected from EcoRI digestion of the wild type HGPRT allele or the rearranged hgprt allele after integration of the hygromycin resistance marker or from BamHI-SalI digestion of the wild type APRT locus are marked. The locations of probe A from the HGPRT coding region, probe B from the 3' flank of HGPRT, probe C from the APRT coding region, and probe D from the 5' flank of APRT are shown under the appropriate genomic loci. HGPRT and APRT coding regions are shown as black rectangles, whereas corresponding 5' (5' UTR) and 3' (3' UTR) untranslated regions of both loci that were amplified by PCR to create the gene targeting constructs are displayed as thin white rectangles. The antibiotic resistance marker HYG is indicated by the thick white box and is appropriately designated, and the corresponding pX-based flanking regions from the L. major dhfr-ts are indicated by the gray shaded boxes.
[View Larger Version of this Image (14K GIF file)]


Fig. 3. Southern blot analysis of the HGPRT locus in wild type and mutant strains. Genomic DNA samples from various strains of L. donovani created in these studies (see Fig. 1) were digested with EcoRI and hybridized to probe A and probe B from the HGPRT locus. The cells from which the genomic DNA samples were obtained are displayed above each lane in the electrophoretogram. Panel A shows the Southern blots of DI700 and APPB2 cells and their progeny, whereas panel B displays the blots of TUBA2 and its derivatives. The locations of probes A and B are indicated in Fig. 2. The sizes of the restriction fragments hybridizing to the HGPRT and APRT probes are shown on the left in base pairs.
[View Larger Version of this Image (47K GIF file)]

It should be noted that after targeting wild type cells with X63-NEO-Delta hgprt or X63-HYG-Delta hgprt, 23 of 24 clones isolated and analyzed by Southern blotting displayed only simple gene replacements, whereas 12 of 15 colonies isolated from hgprt/HGPRT heterozygotes targeted with X63-HYG-Delta hgprt exhibited complex genetic events other than simple gene replacements. These enigmatic genetic alterations in the anomalous cell lines were not analyzed in detail, and the reasons for the large discrepancies in the frequency by which various genetic events were observed during each round of transfection is unknown. However, genetic events that do not involve simple allelic replacements after homologous recombination of an extrachromosomal fragment have been observed previously in Leishmania spp. (7, 12, 23).

Disruption of the wild type APRT locus in lines that were targeted by X63-HYG-Delta aprt was also validated by Southern blot analysis (Fig. 4). aprt/APRT heterozygotes and Delta aprt homozygous knockouts were only derived from the DI700 and TUBA2 lines (see Fig. 1), as APPB2A3 cells already lacked APRT activity (8). Digestion of genomic DNA with SalI and BamHI and hybridization to probe D derived from the 5'-flanking region of APRT (Fig. 2) revealed the presence of the 3.5-kb SalI/BamHI restriction fragment from the wild type allele in all A+/+ and A+/h cells (Fig. 4, probe D). The aprt/APRT heterozygotes contained an additional 1.4-kb SalI band (see Fig. 2) derived from the new allele created by integration of X63-HYG-Delta aprt into the APRT locus. Hybridization of DNA from all of the presumptive Delta aprt null mutants to probe D revealed only the 1.4-kb band expected from the integration of the drug resistance cassette into both alleles of the APRT locus (Fig. 4, probe D). Genetic disruption of wild type APRT alleles was confirmed by hybridization of the same blot to probe C encompassing most of the APRT coding region (Fig. 4, probe C). APRT coding sequences existed only in cells containing one or two wild type APRT copies, whereas the knockout lines TUBA2:H+/+Ah/h and TUBA2:Hn/nAh/h failed to hybridize to probe C (Fig. 4, probe C). The Southern blots of aprt/APRT and Delta aprt derivatives of DI700 cells hybridized to probes C and D have been published previously (21); thus Southern blots of only ak- TUBA2 and its derivatives are depicted in Fig. 4.


Fig. 4. Southern blot analysis of the APRT locus in wild type and mutant strains. DNA prepared from strains of L. donovani generated in these studies (see Fig. 1) was digested with BamHI/SalI and hybridized to probes C and D from the APRT locus (panel C). The cell lines from which genomic DNA was prepared are indicated above each lane in the gel. The locations of probes A, B, C, and D are indicated in Fig. 2. The sizes of the restriction fragments hybridizing to the HGPRT and APRT probes are shown on the left in base pairs.
[View Larger Version of this Image (81K GIF file)]

Enzyme Assays

The phenotypic consequences of HGPRT and APRT replacements were evaluated in most cell lines by direct enzymatic assay. These data paralleled those already reported for the DI700:H+/+A+/+, DI700:H+/nA+/+, DI700:Hn/nA+/+, DI700:Hn/nA+/h, and DI700:Hn/nAh/h (21). A representative HGPRT enzyme assay is presented for the DI700:H+/+A+/+, DI700:H+/nA+/+, DI700:Hn/nA+/+, DI700:Hn/hA+/+, TUBA2:H+/+A+/+, TUBA2:Hn/nA+/+, TUBA2:Hn/nAh/h, and APPB2A3:Hh/n cell lines in Fig. 5A. All null mutants created by single and double gene targeting strategies expressed extremely low activities of HGPRT activity, as expected, whereas the DI700:H+/A+/+ heterozygote expressed an intermediate level of HGPRT activity as compared with the strains that are wild type at the HGPRT locus. APRT deficiencies were established for the TUBA2:Hn/nAh/h and APPB2A3:Hh/n strains, whereas DI700:H+/+A+/+ and TUBA2:H+/+A+/+ expressed equivalent wild type APRT activity (Fig. 5B). An absolute deficiency in APRT could not be established definitively in any cell line expressing HGPRT activity because of the high rate of substrate deamination catalyzed by adenine deaminase activity present in Leishmania parasites (24). All TUBA2-derived cell lines exhibited the expected AK deficiency of the TUBA2 clone (data not shown), while DI700 cells expressed ~6.2 nmol of AK activity/min/mg of protein.


Fig. 5. HGPRT and APRT assays. The abilities of lysates of DI700:H+/+A+/+ (open circle ), DI700:H+/nA+/+ (triangle ), DI700:Hn/hA+/+ (square ), DI700:Hn/nA+/+ (bullet ), TUBA2:H+/+A+/+ (black-triangle), TUBA2:Hn/nA+/+ (black-square), TUBA2:Hn/nAh/h (+), and APPB2A3:Hh/n (×) to phosphoribosylate 20 µM [14C]hypoxanthine (panel A) or of DI700:H+/+A+/+ (open circle ), TUBA2:H+/+A+/+ (black-triangle), TUBA2:Hn/nAh/h (+), and APPB2A3:Hh/n (×) to convert 20 µM [14C]adenine to the nucleotide level (panel B) were determined as described under "Experimental Procedures."
[View Larger Version of this Image (17K GIF file)]

Drug Resistance Phenotypes

As L. donovani HGPRT is known to catalyze the phosphoribosylation of HPP (2, 3, 15), a potential "lead" compound for the treatment of leishmaniasis, the effects of HGPRT deficiency on HPP sensitivity were evaluated in a variety of cell lines. All parental cell lines exhibited an EC50 (effective concentration of drug that inhibits growth by 50%) for HPP of <10 µM and all Delta hgprt null mutants tested exhibited EC50 values for HPP of >2 mM (data not shown). All Delta hgprt lines exhibited cross-resistance to 4-thiopurinol, another pyrazolopyrimidine HGPRT substrate (2, 3). Similarly, cells that were wild type at the APRT locus exhibited EC50 values for APP of <1.0 µM, whereas the EC50 values for all Delta aprt lines were greater than 100 µM. All hgprt/HGPRT and aprt/APRT heterozygotes displayed intermediate EC50 values for HPP (~100 µM) and APP (~1.0 µM), respectively. EC50 values for wild type, heterozygous, and homozygous cell lines at both the HGPRT and APRT loci are similar to those published previously (21). No meaningful variations in HPP riboside sensitivity were observed among wild type and mutant cell lines (data not shown), consistent with the proposed non-phosphoribosylation-based mechanism for incorporation of this nucleoside analog into Leishmania parasites (25).

Growth of Mutant Cell Lines in Purines

The ability of L. donovani to be propagated in completely defined growth medium enables an assessment of their ability to grow under conditions in which the purine source is varied. No differences in the rate or extent of growth were observed among L. donovani strains when the exclusive source of purine in the culture medium was hypoxanthine, guanine, adenine, xanthine, inosine, guanosine, or adenosine.

Radiolabeled Hypoxanthine Incorporation Assay

The capability of Delta hgprt cells to grow in hypoxanthine was somewhat surprising in view of the fact that prokaryotic (26) and mammalian (27) cells lacking HGPRT activity cannot proliferate when exogenous hypoxanthine is the sole source of purine for nucleotide synthesis. As a consequence, the abilities of wild type and Delta hgprt cells to incorporate [14C]hypoxanthine into phosphorylated metabolites was compared. All cell lines tested, including DI700:H+/+A+/+, DI700:Hn/hA+/+, DI700:Hn/nA+/+, TUBA2:Hn/nA+/+, TUBA2:Hn/nAh/h, and APPB2A3:Hh/n, could efficiently incorporate [14C]hypoxanthine into their purine pool, intimating an alternative mechanism for hypoxanthine conversion to the nucleotide level in Delta hgprt cells (Fig. 6). The uptake of other purine bases was not evaluated for any of these cell lines, as adenine, the natural substrate of APRT, is funneled by Leishmania through hypoxanthine prior to incorporation into the nucleotide pool, whereas guanine is converted to xanthine, which is phosphoribosylated by XPRT, an enzyme whose function in intact parasites cannot yet be evaluated with genetic tools (8, 28, 29).


Fig. 6. Incorporation of [14C]hypoxanthine by wild type and mutant cell lines. The capacities of intact DI700:H+/+A+/+ (open circle ), DI700:Hn/hA+/+ (square ), DI700:Hn/nA+/+ (bullet ), TUBA2:Hn/nA+/+ (black-square), TUBA2:Hn/nAh/h (+), and APPB2A3:Hh/n (×) cells to convert 1.8 µM [14C]hypoxanthine to the nucleotide level were conducted as described under "Experimental Procedures." Each time point reflects the amount of radiolabel in phosphorylated metabolites incorporated by approximately 107 cells.
[View Larger Version of this Image (23K GIF file)]

To further illuminate this hypoxanthine uptake into Delta hgprt cells, the ability of high concentrations of nonradiolabeled naturally occurring purines to interfere with [14C]hypoxanthine incorporation into these cell lines was compared. 100 µM concentrations of either hypoxanthine, adenine, adenosine, inosine, or guanine inhibited the incorporation of 1.8 µM [14C]hypoxanthine into all cell lines tested by 80-90%. Conversely, 100 µM xanthine did not substantially alter the ability of wild type cells to phosphoribosylate [14C]hypoxanthine, whereas all of the Delta hgprt strains were affected noticeably. Representative [14C]hypoxanthine incorporation data are presented in Fig. 7 for the wild type DI700:H+/+A+/+ and triple mutant TUBA2:Hn/nAh/h cell lines. Neither HPP or HPP riboside affected hypoxanthine incorporation rates into any of the L. donovani cell lines (data not shown).


Fig. 7. Effect of purine nucleobases and nucleosides on [14C]hypoxanthine incorporation by DI700:H+/+A+/+, APPB2A3:Hh/n, and TUBA2:Hn/nAh/h cells. [14C]Hypoxanthine incorporation by DI700:H+/+A+/+ (panel A), APPB2A3:Hh/n (panel B), and TUBA2:Hn/nAh/h cells (panel C) was determined in the absence (bullet ) or presence of either adenine (open circle ), guanine (black-square), hypoxanthine (square ), xanthine (black-triangle), adenosine (triangle ]), or inosine (+). [14C]hypoxanthine was present in the assay mixture at 1.8 µM, while nonradiolabeled purines were added to a final concentration of 100 µM. Each data point reflects the amount of radiolabel converted to the nucleotide level by 107 parasites.
[View Larger Version of this Image (16K GIF file)]

As preliminary experiments (see Fig. 7) implied that xanthine in the culture medium selectively interfered with the ability of Delta hgprt cells to incorporate [14C]hypoxanthine, the effects of increasing concentrations of xanthine on [14C]hypoxanthine uptake were compared for wild type DI700:H+/+A+/+ and 2 Delta hgprt strains, DI700:Hn/hA+/+, and DI700:Hn/nA+/+ cells. As demonstrated in Fig. 8, xanthine could block [14C]hypoxanthine incorporation into nucleotides by >95% at high concentrations in DI700:Hn/hA+/+ and DI700:Hn/nA+/+ cells, whereas wild type DI700:H+/+A+/+ cells expressed a significant xanthine-refractory [14C]hypoxanthine uptake component.


Fig. 8. Effect of xanthine on [14C]hypoxanthine incorporation by wild type and Delta hgprt L. donovani. [14C]hypoxanthine incorporation into DI700:H+/+A+/+ (open circle ), DI700:Hn/hA+/+ (square ), and DI700:Hn/nA+/+ (bullet ) cells was determined as a function of xanthine concentration. The data were normalized the amount of radiolabel incorporated by each strain in the absence of xanthine.
[View Larger Version of this Image (19K GIF file)]


DISCUSSION

The ability of Leishmania to undergo efficient homologous recombination (7, 10) and the relatively recent development of methodologies to transfect these parasites with exogenous DNA (13, 14) have enabled this genetic dissection of the purine salvage pathway by targeted gene replacement strategies. This genetic analysis has been greatly facilitated by the availability of mutationally derived cell lines deficient in either APRT (8) or AK (17) activity, thereby expediting the construction of cell lines with multiple mutations. Previous biochemical, genetic, and radiolabel incorporation studies have implied that HGPRT, APRT, and AK are three enzymes that play primary roles in purine salvage by L. donovani (8, 17, 28). XPRT may play an important role in accessing host guanylate pools (28, 29), but adenylate nucleotides are the predominant host purines. A nucleoside phosphotransferase activity has also been detected in L. donovani, albeit in low amounts, but is only known to recognize the purine analog, HPP riboside (25). As the L. donovani HGPRT (15) and APRT (16) and their respective flanking sequences have been isolated, a plethora of Delta hgprt and Delta aprt homozygous null mutants lines have been generated by targeted gene replacement within the wild type, aprt-, and ak- backgrounds. Strains constructed for this genetic evaluation of the purine pathway include: Delta hgprt, Delta aprt, Delta hgprt/Delta aprt (as well as aprt-/Delta hgprt), Delta hgprt/ak-, Delta aprt/ak-, and Delta hgprt/Delta aprt/ak-, and all of the obligatory heterozygous progenitors. From a biochemical perspective, targeted gene replacement allowed the creation of mutant null phenotype parasites defective in the three purine salvage enzymes in every conceivable combination, including three single mutants, hgprt-, aprt-, and ak-; three double mutants, hgprt-/aprt-, hgprt-/ak-, and aprt--/ak-; and one triple mutant, hgprt-/aprt-/ak- (Fig. 1). All of these strains are theoretically syngeneic except for the rearranged HGPRT and APRT loci encompassing the drug resistance cassettes and for the uncharacterized mutations that conferred deficiencies in either AK or APRT activity.

Critical to the creation of L. donovani strains with multiple mutations was the ability to generate homozygous null mutants at either the HGPRT or APRT locus with only a single targeting construct. This preserved the other drug resistance marker employed in these studies for subsequent genetic manipulations, thereby allowing the creation of cells with more than one homozygous mutation, and resulted in a substantial savings both in time required for the construction of all of the mutant cell lines and in financial resources. Eliminating both alleles with only a single targeting vector required first the creation of the heterozygotes by homologous recombination of drug resistance cassettes containing 5'- and 3'-flanking sequences of HGPRT or APRT followed by selection for LOH in subversive substrate. LOH has been demonstrated previously in Leishmania at the HGPRT, APRT, and dihydrofolate reductase-thymidylate synthase loci (21, 30), and these present studies embellish the previous findings by demonstrating that LOH at the HGPRT and APRT loci is neither marker- nor cell line-specific. The mechanism for LOH in Leishmania is not known but could include chromosome loss, chromosome nondisjunction, gene deletion, mitotic recombination, gene conversion, or possibly homologous recombination of stably maintained episomal DNAs originating either from the targeting construct or the rearranged chromosome locus. Simple chromosome loss (31), chromosome loss followed by duplication (31, 32), and mitotic recombination (32, 33) have all been demonstrated as mechanisms of LOH in mammalian cell systems. Overall, the ability to create null mutants with single targeting constructs greatly facilitates genetic investigations into complex and divagating metabolic pathways, such as that for purine salvage, and the availability of additional drug resistance markers for Leishmania parasites (34-36) should allow the construction of knockout parasites bearing even more than the 2 homozygous mutations.

The genetic studies with HGPRT and APRT targeting constructs in L. donovani have revealed some unique and unexpected features of the purine salvage pathway in this protozoan parasite. Foremost, mutants defective in HGPRT, APRT, and/or AK activity retain the capacity to proliferate in completely defined medium in which the sole exogenous purine source is any of the four naturally occurring purine nucleobases, hypoxanthine, xanthine, guanine, or adenine, or the nucleosides adenosine, inosine, or guanosine. In contrast, mammalian cells rendered pharmacologically auxotrophic for purines with inhibitors of purine biosynthesis cannot salvage hypoxanthine through HGPRT (27), adenine through APRT (37), or adenosine through AK (38) when the germane enzyme is missing. Indeed, this pharmacologically induced purine deprivation has served as a valuable positive selectable marker for expression of these purine salvage enzymes in animal cell systems (27, 37-39). The viability of the mutant L. donovani strains in any single purine can be attributed to their ability to incorporate hypoxanthine efficiently into the purine pool. HGPRT-deficient mammalian cells cannot incorporate hypoxanthine (8, 27, 39). The uptake of other purine bases was not evaluated in these mutant strains, since it has been previously demonstrated that wild type L. donovani promastigotes funnel adenine through hypoxanthine prior to incorporation into the nucleotide pool and metabolize guanine and xanthine through XPRT (28, 29). The channeling of other purines into hypoxanthine by L. donovani promastigotes is supported by our competition studies that demonstrate that excess adenosine, inosine, and adenine are as effective as equimolar concentrations of hypoxanthine in blocking [14C]hypoxanthine incorporation into nucleotides (see Fig. 7). Guanine is a bit less effective at impeding [14C]hypoxanthine incorporation, presumably because it is rapidly oxidatively deaminated to xanthine (28, 29). The channeling of inosine, adenine, and adenosine into hypoxanthine can be respectively ascribed to the high levels of of nucleoside hydrolase (40), adenine deaminase (24), and adenosine hydrolase/phosphorylase (17) activities present in L. donovani promastigotes. None of these enzymes is expressed by mammalian cells.

The mechanism by which hypoxanthine, as well as the purines that are transformed into hypoxanthine, are assimilated into the nucleotide pool in Delta hgprt/Delta aprt L. donovani is currently under study. The fact that high concentrations of xanthine only partially inhibit [14C]hypoxanthine incorporation into wild type parasites but virtually obliterate [14C]hypoxanthine uptake into Delta hgprt strains (Fig. 8) implies that XPRT, an enzyme that is expressed in L. donovani (41), plays a central, but obviously not exclusive, role in hypoxanthine metabolism in this protozoan parasite. Two mechanisms could account for this inhibition of [14C]hypoxanthine uptake by xanthine; either XPRT recognizes hypoxanthine as a substrate, or hypoxanthine is oxidized to xanthine prior to its phosphoribosylation. The latter hypothesis is unlikely, however, since L. donovani promastigotes lack detectable xanthine oxidase/dehydrogenase activity (41). The different extents by which xanthine inhibits [14C]hypoxanthine incorporation into wild type and Delta hgprt strains can be imputed to the fact that the former expresses two enzymes that phosphoribosylate hypoxanthine, whereas the Delta hgprt mutants lacks the xanthine-refractory pathway, i.e. HGPRT.

Little is known about XPRT from Leishmania, although mammalian cells lack the activity (41). However, it would appear that the enzyme might serve as a target for the selective incorporation of cytotoxic xanthine analogs, such as 6-thioxanthine, which is phosphoribosylated by the hypoxanthine-guanine-xanthine PRT (HGXPRT) of Toxoplasma gondii (42, 43). Tuttle and Krenitsky have chromatographically distinguished the L. donovani XPRT and HGPRT activities, but the substrate specificity of XPRT could not be evaluated due to the inherent instability of the native enzyme in solution (41). The L. donovani HGPRT, however, does not recognize xanthine (15, 41). Attempts are currently under way to isolate and overexpress the XPRT gene from L. donovani to provide sufficient recombinant protein for ultimate biochemical and structural characterization.

Enzyme and radiolabel incorporation studies with other protozoan parasites have revealed considerable differences in the purine salvage pathways among various genera (1). Thus, conclusions drawn from these studies on the purine pathway of L. donovani promastigotes are unlikely to have general applicability to other parasites, except perhaps to other parasites of the Trypanosomatidae family, e.g. Trypanosoma brucei, the etiologic agent of African sleeping sickness, and Trypanosoma cruzi, the parasite that causes Chagas disease. Moreover, there are differences between the purine salvage pathways of promastigotes and amastigotes, the latter being the infective form of the parasite. For instance, L. donovani amastigotes lack adenine deaminase and cannot convert, therefore, other purines into hypoxanthine (44). A similar genetic dissection of the purine pathway in amastigotes by targeted gene replacement will be undertaken with L. mexicana, a species that can be propagated as promastigotes, axenic amastigote-like forms (45), and amastigotes in macrophage lines (46), and the genes encoding L. mexicana HGPRT and APRT have already been isolated for these purposes. Extensive genetic studies on the purine pathway of other protozoan parasites have not been accomplished, although mutations in either AK (47) or HGXPRT (42, 43) have no apparent effect on survival of T. gondii. Preliminary experiments do suggest, however, that double knock-outs of both AK and HGXPRT activities may be lethal.2 If these preliminary experiments are sustained, the HGXPRT activity plays a sufficient but not obligatory role in purine salvage in T. gondii. In contrast, neither HGPRT, APRT, nor AK, alone or in any combination, are essential to purine salvage by or survival of L. donovani promastigotes.

The purine auxotrophy of Leishmania and its unique purine salvage pathway offers a number of targets for therapeutic consideration. One therapeutic paradigm has been inhibitor design to block purine acquisition from the host. The channeling of extracellular purines through hypoxanthine (28, 39) had suggested that HGPRT would be an appropriate target for inhibitor design, but our genetic investigations demonstrate, at least in promastigotes, that specific inhibitors of HGPRT alone would be therapeutically ineffective. Similar conclusions can be drawn about the potential effectiveness of APRT and AK inhibitors as a consequence of these studies. Indeed, targeting all three enzymes in combination may not be a valid therapeutic paradigm. However, if XPRT in conjunction with HGPRT proves indispensable to purine salvage by this protozoan parasite, one might envision that a common mechanism-based inhibitor might have thereapeutic potential or that targeting both enzymes with a combination of inhibitors might be a rational thereapeutic strategy. Targeting multiple steps in a metabolic pathway has considerable precedence in antiparasitic therapies (48, 49). Testing XPRT function in both wild type and Delta hgprt backgrounds can be accomplished by similar targeted gene replacement approaches, once the L. donovani XPRT is isolated.


FOOTNOTES

*   This work was supported in part by a grant from the Burroughs Wellcome Fund and by Grant AI-23682 from NIAID, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Burroughs Wellcome Fund Scholar in Molecular Parasitology. To whom correspondence should be addressed. Tel.: 503-494-8437; Fax: 503-494-8393; E-mail: ullmanb{at}ohsu.edu.
1   The abbreviations used are: HPP, allopurinol; AK, adenosine kinase; APP, 4-aminopyrazolopyrimidine; APRT, adenine phosphoribosyltransferase; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; HGXPRT, hypoxanthine-guanine-xanthine phosphoribosyltransferase; kb, kilobase pair(s); LOH, loss-of-heterozygosity; PCR, polymerase chain reaction; PRT, phosphoribosyltransferase; XPRT, xanthine phosphoribosyltransferase.
2   D. S. Roos, personal communication.

ACKNOWLEDGEMENTS

We thank Liliana Tolmasky and Francy Pesek-Jardim for help with the extensive cell culture manipulations required for these investigations and Sarah Shih and Thomas Gilberts for help in figure preparation.


REFERENCES

  1. Berens, R. L., Krug, E. C., and Marr, J. J. (1995) in Biochemistry of Parasitic Organisms and Its Molecular Foundations (Marr, J. J., and Muller, M., eds), pp. 89-117, Academic Press Limited, London
  2. Marr, J. J., and Berens, R. L. (1983) Mol. Biochem. Parasitol. 7, 339-356 [Medline] [Order article via Infotrieve]
  3. Ullman, B. (1984) Pharmaceut. Res. 1, 194-203 [CrossRef]
  4. Palella, T. D., and Fox, I. H. (1989) in The Metabolic Basis of Inherited Diseases (Scriver, C. S., Beaudet, A. L., Sly, W. S., and Valle, D., eds), 6th Ed., pp. 965-1006, McGraw Hill Book Co., New York
  5. Martinez, S., and Marr, J. J. (1992) N. Engl. J. Med. 326, 741-744 [Abstract]
  6. Gallerano, R. H., Sosa, R. R., and Marr, J. J. (1990) Am J. Trop. Med. Hyg. 43, 159-166 [Medline] [Order article via Infotrieve]
  7. Cruz, A., and Beverley, S. M. (1990) Nature 348, 171-173 [CrossRef][Medline] [Order article via Infotrieve]
  8. Iovannisci, D. M., Goebel, D., Kaur, K., Allen, K., and Ullman, B. (1984) J. Biol. Chem. 259, 14617-14623 [Abstract/Free Full Text]
  9. Iovannisci, D. M., and Beverley, S. M. (1989) Mol. Biochem. Parasitol. 34, 177-188 [CrossRef][Medline] [Order article via Infotrieve]
  10. Tobin, J. F., Laban, A., and Wirth, D. F. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 864-868 [Abstract]
  11. Cruz, A., Coburn, C. M., and Beverley, S. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7170-7174 [Abstract]
  12. Curotto de Lafaille, M. A., and Wirth, D. F. (1992) J. Biol. Chem. 267, 23839-23846 [Abstract/Free Full Text]
  13. Laban, A., Tobin, J. F., de Lafaille, M. A. C., and Wirth, D. F. (1990) Nature 343, 572-574 [CrossRef][Medline] [Order article via Infotrieve]
  14. Kapler, G. M., Coburn, C. M., and Beverley, S. M. (1990) Mol. Cell. Biol. 10, 1084-1094 [Medline] [Order article via Infotrieve]
  15. Allen, T. E., Hwang, H.-Y., Jardim, A., Olafson, R., and Ullman, B. (1995) Mol. Biochem. Parasitol. 73, 133-145 [CrossRef][Medline] [Order article via Infotrieve]
  16. Allen, T. E., Hwang, H.-Y., Jardim, A., and Ullman, B. (1995) Mol. Biochem. Parasitol. 74, 99-103 [CrossRef][Medline] [Order article via Infotrieve]
  17. Iovannisci, D. M., and Ullman, B. (1984) Mol. Biochem. Parasitol. 12, 139-151 [CrossRef][Medline] [Order article via Infotrieve]
  18. Iovannisci, D. M., and Ullman, B. (1983) J. Parasitol. 69, 633-636 [Medline] [Order article via Infotrieve]
  19. Wilson, K., Collart, F., Huberman, E., Stringer, J., and Ullman, B. (1991) J. Biol. Chem. 266, 1665-1671 [Abstract/Free Full Text]
  20. Hanson, S., Adelman, J., and Ullman, B. (1992) J. Biol. Chem. 267, 2350-2359 [Abstract/Free Full Text]
  21. Hwang, H.-Y., Gilberts, T., Jardim, A., Shih, S., and Ullman, B. (1996) J. Biol. Chem. 271, 30840-30846 [Abstract/Free Full Text]
  22. Allen, T., Henschel, E. V., Coons, T., Cross, L., Conley, J., and Ullman, B. (1989) Mol. Biochem. Parasitol. 33, 273-281 [Medline] [Order article via Infotrieve]
  23. Cruz, A. K., Titus, R., and Beverley, S. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1599-1603 [Abstract]
  24. Kidder, G. W., and Nolan, L. L. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 3670-3672 [Abstract]
  25. Nelson, D. J., LaFon, S. W., Tuttle, J. V., Miller, W. H., Miller, R. L., Krenitsky, T. A., Elion, G. B., Berens, R. L., and Marr, J. J. (1979) J. Biol. Chem. 254, 11544-11549 [Medline] [Order article via Infotrieve]
  26. Jochimsen, B., Nygaard, P., and Vestergaard, T. (1975) Mol. Gen. Genet. 143, 85-91 [Medline] [Order article via Infotrieve]
  27. Littlefield, J. W. (1964) Science 145, 709-710
  28. Marr, J. J., Berens, R. L., and Nelson, D. J. (1978) Biochim. Biophys. Acta 544, 360-371 [Medline] [Order article via Infotrieve]
  29. LaFon, S. W., Nelson, D. J., Berens, R. L., and Marr, J. J. (1982) Biochem. Pharmacol. 31, 231-238 [Medline] [Order article via Infotrieve]
  30. Guieros-Filho, F. J., and Beverley, S. M. (1996) Mol. Cell. Biol. 16, 5655-5663 [Abstract]
  31. Campbell, E. E., and Worton, R. G. (1981) Mol. Cell. Biol. 1, 336-346 [Medline] [Order article via Infotrieve]
  32. Wasmuth, J. J., and Hall, L. V. (1984) Cell 36, 697-707 [Medline] [Order article via Infotrieve]
  33. Nelson, F. K., Frankel, W., and Rajan, T. V. (1989) Mol. Cell. Biol. 9, 1284-1288 [Medline] [Order article via Infotrieve]
  34. Freedman, D. J., and Beverley, S. M. (1993) Mol. Biochem. Parasitol. 62, 37-44 [CrossRef][Medline] [Order article via Infotrieve]
  35. Souza, A. E., Bates, P. A., Coombs, G. H., and Mottram, J. C. (1994) Mol. Biochem. Parasitol. 63, 213-220 [Medline] [Order article via Infotrieve]
  36. Joshi, P. B., Webb, J. R, Davies, J. E., and McMaster, W. R. (1995) Gene (Amst.) 156, 145-149 [CrossRef][Medline] [Order article via Infotrieve]
  37. Kusano, T., Long, C., and Green, H. (1971) Proc. Natl. Acad. Sci. U. S. A. 68, 82-86 [Abstract]
  38. Chan, T.-S., Creagan, R. P., and Reardon, M. P. (1978) Somat. Cell Genet. 4, 1-12 [Medline] [Order article via Infotrieve]
  39. Caskey, C. T., and Kruh, G. D. (1979) Cell 16, 1-9 [CrossRef][Medline] [Order article via Infotrieve]
  40. Koszalka, G. W., and Krenitsky, T. A. (1979) J. Biol. Chem. 254, 8185-8193 [Medline] [Order article via Infotrieve]
  41. Tuttle, J. V., and Krenitsky, T. A. (1979) J. Biol. Chem. 255, 909-916 [Free Full Text]
  42. Pfefferkorn, E. R., and Borotz, S. (1994) Exp. Parasitol. 79, 374-382 [CrossRef][Medline] [Order article via Infotrieve]
  43. Donald, R. G. K., Carter, D., Ullman, B., and Roos, D. S. (1996) J. Biol. Chem. 271, 14010-14019 [Abstract/Free Full Text]
  44. Looker, D. L., Berens, R. L., and Marr, J. J. (1983) Mol. Biochem. Parasitol. 9, 15-23 [CrossRef][Medline] [Order article via Infotrieve]
  45. Bates, P. A., Robertson, C. D., Tetley, L., and Coombs, G. H. (1992) Parasitol. 105, 193-202
  46. Chang, K.-P. (1980) Science 209, 1240-1242 [Medline] [Order article via Infotrieve]
  47. Schwartzman, J. D., and Pfefferkorn, E. R. (1982) Exp. Parasitol. 53, 77-86 [CrossRef][Medline] [Order article via Infotrieve]
  48. Geary, T. G., and Jensen, J. D. (1986) in Chemotherapy of Parasitic Diseases (Campbell, W. C., and Rew, R. S., eds), pp. 87-114, Plenum Press, New York
  49. Kovacs, J. A., and Masur, H. (1986) in Chemotherapy of Parasitic Diseases (Campbell, W. C., and Rew, R. S., eds), pp. 139-158, Plenum Press, New York

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.